Clinical Trial Update: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of vorinostat (Zolinza) with Doxil and bortezomib for relapsed/refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Velcade (bortezomib)
• Zolinza (vorinostat)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN